# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...
Teva Pharmaceutical reported Q2 2024 sales of $4.16 billion, surpassing the $4.06 billion consensus. Revenue rose 7% YoY, drive...
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...
Outlook for 2024 Non-GAAP Results $ billions, except EPS or as noted July 2024 Outlook January 2024 Outlook ...